



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Appln. of: Anita Melikian ET AL.

Appln. No.: 10/743,281

Filed: 12/22/03

For: INHIBITORS OF HUMAN  
TUMOR-EXPRESSED  
CCXCKR2

Examiner: Unassigned

Art Unit: 1616

Attorney Docket No: 10709/63

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

In accordance with the duty of disclosure under 37 C.F.R. §1.56 and §§1.97-1.98, and more particularly in accordance with 37 C.F.R. §1.97(b), Applicants hereby cite the following reference(s):

**U.S. Patents**

No.	Date	Name
3,135,608	06/02/64	Dickard
6,215,658	04/10/01	Bodini

No.	Date of Publication	Patentee/Applicant/Assignee
WO 01/98272 A1	06/14/01	Eriksson et al.
WO 03/007888 A2	07/22/02	Stevenson et al.
WO 02/24649 A1	09/06/01	Boss et al.
WO 01/55107 A2	01/29/01	Lundstedt et al.

Applicants are enclosing Form PTO-1449 (one sheet), along with a copy of each listed reference for which a copy is required under 37 C.F.R. §1.98(a)(2). As each of the listed references is in English, no further commentary is believed to be necessary, 37 C.F.R §1.98(a)(3). Applicants respectfully request the Examiner's consideration of the above reference(s) and entry thereof into the record of this application.

By submitting this Statement, Applicants are attempting to fully comply with the duty of candor and good faith mandated by 37 C.F.R. §1.56. As such, this Statement is not intended to constitute an admission that any of the enclosed references, or other

information referred to therein, constitutes "prior art" or is otherwise "material to patentability," as that phrase is defined in 37 C.F.R. §1.56(a).

For purposes of 37 C.F.R. §1.704(d), Applicants certify that each item of information contained in this Statement was cited in a communication from a foreign patent office in a counterpart application, and that this communication was not received by any individual designated in 37 C.F.R. §1.56(c) more than thirty days prior to the filing of this Statement (a copy of any foreign communication first citing a listed reference is attached for the Examiner's reference).

Applicants have calculated no fee to be due in connection with the filing of this Statement. However, the Director is authorized to charge any fee deficiency associated with the filing of this Statement to a deposit account, as authorized in the Transmittal accompanying this Statement.

Respectfully submitted,

July 27, 2006

Date



K. Shannon Mrksich, Ph.D., Esq.

(Reg. No. 36,675)

Attorney for Applicants



FORM PTO-1449	SERIAL NO. 10/743,281	CASE NO. 10709/63
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT	FILING DATE December 22, 2003	GROUP ART UNIT 1616
(use several sheets if necessary)		APPLICANT(S): Anita Melikian et al.

## REFERENCE DESIGNATION

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER <small>Number-Kind Code (if known)</small>	DATE	NAME	CLASS/ SUBCLASS	FILING DATE
	A1	3,135,608	06/02/64	Dickard		
	A2	6,215,658	04/10/01	Bodini		

## FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER <small>Number-Kind Code (if known)</small>	DATE	COUNTRY	CLASS/ SUBCLASS	TRANSLATION YES OR NO
	A3	WO 01/98272 A1	06/14/01	PCT		N
	A4	WO 03/007888 A2	07/22/02	PCT		N
	A5	WO 02/24649 A1	09/06/01	PCT		N
	A6	WO 01/55107 A2	01/29/01	PCT		N

EXAMINER INITIAL	OTHER ART – NON PATENT LITERATURE DOCUMENTS <small>(Include name of author, title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date page(s), volume-issue number(s), publisher, city and/or country where published.</small>	

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.